432
Views
0
CrossRef citations to date
0
Altmetric
Review Article

Comment and Response: (Lugo-Radillo & Cortez-Lopez, 2020) Long-Term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-Containing Mushrooms

ORCID Icon, , &

References

  • Breakey, W. R., H. Goodell, P. C. Lorenz, and P. R. McHugh. 1974. Hallucinogenic drugs as precipitants of schizophrenia. Psychological Medicine 4 (3):255–61. doi:10.1017/s0033291700042938.
  • Carhart-Harris, R., B. Giribaldi, R. Watts, M. Baker-Jones, A. Murphy-Beiner, R. Murphy, D. J. Martell, A. Blemings, D. Erritzoe, and D. J. Nutt. 2021. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine 384 (15):1402–11. doi:10.1056/NEJMoa2032994.
  • Carhart-Harris, R. L., and D. J. Nutt. 2010. User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study. Journal of Substance Use 15 (4):283–300. doi:10.3109/14659890903271624.
  • ClinicalTrials.gov. 2021. Clinical Trial Search Results for “psychedelic OR LSD OR mescaline OR psilocybin OR DMT.
  • Fink, M., J. Simeon, W. Haque, and T. Itil. 1966. Prolonged adverse reactions to LSD in psychotic subjects. Archives of General Psychiatry 15 (5):450–54. doi:10.1001/archpsyc.1966.01730170002002.
  • Gewandter, J. S., M. P. McDermott, R. A. Kitt, J. Chaudari, J. G. Koch, S. R. Evans, R. A. Gross, J. D. Markman, D. C. Turk, and R. H. Dworkin. 2017. Interpretation of CIs in clinical trials with non-significant results: Systematic review and recommendations. BMJ Open 7 (7):e017288. doi:10.1136/bmjopen-2017-017288.
  • Giancola, N. B., C. J. Korson, J. P. Caplan, and C. A. McKnight. 2021. A “trip” to the intensive care unit: An intravenous injection of psilocybin. Journal of the Academy of Consultation-Liaison Psychiatry 62 (3):370–71. doi:10.1016/j.jaclp.2020.12.012.
  • Halpern, J. H., A. G. Lerner, and T. Passie. 2018. A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. Current Topics in Behavioral Neurosciences 36:333–60. doi:10.1007/7854_2016_457.
  • Insel, T. R. 2014. The NIMH research domain criteria (RDoC) project: Precision medicine for psychiatry. American Journal of Psychiatry 171 (4):395–97. doi:10.1176/appi.ajp.2014.14020138.
  • Johansen, P., and T. S. Krebs. 2015. Psychedelics not linked to mental health problems or suicidal behavior: A population study. Journal of Psychopharmacology 29 (3):270–79. doi:10.1177/0269881114568039.
  • Johnson, M., W. Richards, and R. Griffiths. 2008. Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology 22 (6):603–20. doi:10.1177/0269881108093587.
  • Leonard, H. L., and J. L. Rapoport. 1987. Relief of obsessive-compulsive symptoms by LSD and psilocin. American Journal of Psychiatry 144 (9):1239–40. doi:10.1176/ajp.144.9.1239b.
  • Litjens, R. P., T. M. Brunt, G. J. Alderliefste, and R. H. Westerink. 2014. Hallucinogen persisting perception disorder and the serotonergic system: A comprehensive review including new MDMA-related clinical cases. European Neuropsychopharmacology 24 (8):1309–23. doi:10.1016/j.euroneuro.2014.05.008.
  • Lugo-Radillo, P., and J. M. Cortes-Lopez. 2021. Long-term amelioration of OCD symptoms in a patient with chronic consumption of psilocybin-containing mushrooms. Journal of Psychoactive Drugs 53 (2):146–48. doi:10.1080/02791072.2020.1849879.
  • Moreno, F. A., and P. L. Delgado. 1997. Hallucinogen-induced relief of obsessions and compulsions. American Journal of Psychiatry 154 (7):1037–38. doi:10.1176/ajp.154.7.1037b.
  • Moreno, F. A., C. B. Wiegand, E. K. Taitano, and P. L. Delgado. 2006. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry 67 (11):1735–40. doi:10.4088/jcp.v67n1110.
  • Nichols, D. E. 2016. Psychedelics. Pharmacological Reviews 68 (2):264–355. doi:10.1124/pr.115.011478.
  • Nutt, D. J., L. A. King, and L. D. Phillips. 2010. Drug harms in the UK: A multicriteria decision analysis. The Lancet 376 (9752):1558–65. doi:10.1016/s0140-6736(10)61462-6.
  • Vardy, M. M., and S. R. Kay. 1983. LSD psychosis or LSD-induced schizophrenia? A multimethod inquiry. Archives of General Psychiatry 40 (8):877–83. doi:10.1001/archpsyc.1983.01790070067008.
  • Wilcox, J. A. 2014. Psilocybin and obsessive compulsive disorder. Journal of Psychoactive Drugs 46 (5):393–95. doi:10.1080/02791072.2014.963754.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.